Medical Information
United States

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

Existe información en español para pacientes y cuidadores, para acceder, haga clic sobre “Select” al lado de “I am a U.S. Patient / Caregiver”.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

CAVERJECT® IMPULSE Highlights (alprostadil)


These highlights do not include all the information needed to use CAVERJECT IMPULSE safely and effectively. See full prescribing information for CAVERJECT IMPULSE.

CAVERJECT IMPULSE® (alprostadil) for injection, for intracavernosal use
Initial U.S. Approval: 1981


Warnings and Precautions, Needle Breakage (5.7)05/2016
Warnings and Precautions, Benzyl Alcohol (5.8)10/2016


CAVERJECT IMPULSE is a prostaglandin E1 agonist indicated

  • For the treatment of erectile dysfunction (1.1)
  • As an adjunct to other diagnostic tests in the diagnosis of erectile dysfunction (1.2).


  • Determine the most suitable dose and formulation of CAVERJECT to use (2.1)
  • Administer first intracavernosal injections in the physician's office and titrate the dose for each patient to the lowest effective dose (2.1)
  • Dosage for erectile dysfunction (2.2):
    • Erectile dysfunction of vasculogenic, psychogenic, or mixed etiology:
      Initiate dosing with 2.5 mcg
    • Erectile dysfunction of pure neurogenic etiology (spinal cord injury):
      Initiate dosing with 1.25 mcg
  • Follow dose titration procedures for each type of erectile dysfunction and determine the maintenance dosage for erectile dysfunction for patient home use in the physician's office (2.2)
  • The recommended frequency of injection is no more than 3 times weekly, with at least 24 hours between each dose (2.2)
  • While on self-injection treatment, the patient should visit the prescribing physician's office every 3 months to assess the efficacy and safety of the therapy (2.2)
  • Instruct the patient on proper use and assess that they are well trained in the self-injection technique prior to initiation of at-home use (2.3)
  • To diagnose erectile dysfunction (pharmacologic testing), inject CAVERJECT IMPULSE intracavernosally and monitor patients for the occurrence of an erection (2.4)
  • Follow procedure for CAVERJECT IMPULSE syringe preparation (2.5)


For injection: 10 mcg or 20 mcg freeze-dried powder for reconstitution in a dual-chamber syringe (3)


  • Known hypersensitivity to the drug (4)
  • Men who have conditions that predispose them to priapism, such as sickle cell anemia or sickle cell trait, multiple myeloma, or leukemia (4)
  • Treatment of erectile dysfunction in men with fibrotic conditions of the penis, such as anatomical deformation, angulation, cavernosal fibrosis, or Peyronie's disease (4)
  • Men with penile implants (4)


  • Prolonged erection and priapism have occurred in patients receiving CAVERJECT. To minimize the chances of this occurring, titrate CAVERJECT IMPULSE slowly to the lowest effective dose (2.1). Advise patients to seek immediate medical assistance for an erection that persists longer than 4 hours (5.1)
  • Penile fibrosis has occurred in patients receiving CAVERJECT. Follow patients regularly to detect signs of penile fibrosis. Discontinue in patients who develop penile angulation or cavernosal fibrosis (5.2)
  • Hypotension - injections of CAVERJECT IMPULSE can lead to increased peripheral blood levels of alprostadil, especially in patients with significant corpora cavernosa venous leakage. Avoid use in patients with known cavernosal venous leakage (5.3)
  • Injection site bleeding may occur in patients taking anticoagulants, such as warfarin or heparin. Compress the site of injection with an alcohol swab or sterile gauze for 5 minutes (5.4)
  • Cardiovascular risk related to underlying medical conditions - Underlying treatable medical causes of erectile dysfunction should be diagnosed and treated prior to initiation of therapy (5.5)
  • Risks of use in combination with other vasoactive medications injected intracavernosally - Safety and efficacy of combinations of CAVERJECT and other vasoactive agents have not been systematically studied. Use of such combinations is not recommended (5.6)
  • Risk of needle breakage – CAVERJECT IMPULSE uses a superfine needle and cases of needle breakage have been reported. Careful instruction in proper patient handling and injection techniques may minimize this risk (5.7)
  • Benzyl alcohol – CAVERJECT IMPULSE contains benzyl alcohol as a preservative (5.8)
  • Counseling patients about sexually transmitted diseases. Counseling of patients about the protective measures necessary to guard against sexually transmitted disease including the Human Immunodeficiency Virus (HIV) is advised. (5.9)


Most common (≥10%) adverse reactions: penile pain (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer at (1-800-438-1985 and or FDA at 1-800-FDA-1088 or

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 10/2016

Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event